August 3, 2012 / 9:32 PM / 8 years ago

Sarepta Therapeutics gets stop work order from US defense dept

* Says the order related to Ebola contract

* Shares fall 6 pct in after-market trade

Aug 3 (Reuters) - Sarepta Therapeutics Inc, which gets a majority of its revenue from government drug research contracts, said the United States Department of Defense ordered it to stop work on the Ebola portion of a contract, citing funding constraints.

Sarepta’s shares fell 6 percent to a low of $8.20 in after-market trade. They closed at $8.73 on the Nasdaq on Friday.

The stop-work order does not apply to the ongoing Marburg portion funded under the same hemorrhagic fever virus therapeutics contract, Sarepta said in a regulatory filing.

The stop-work order will remain in effect till Sept. 1, before which the DoD will either lift it, extend the stop-work period or end the Ebola portion of the contract.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below